top of page

Insights & Updates


Surviving the Phase II Cliff: Why So Many Promising Drugs Fail — and What We Can Do About It
For translational leaders, generating decision-quality data before risking millions in clinical trials is crucial. De-Risk Antibody Development with Tissue Insights Platform.
Featured
Search


Operationalizing Translational Success: Why the 5R Framework Demands a Tissue-First Approach
For over a decade, the pharmaceutical industry has universally admired the structured translational frameworks pioneered by industry leaders. When AstraZeneca instituted the "5R Framework" (Right Target, Right Tissue, Right Safety, Right Patient, Right Commercial) and Pfizer deployed their "Three Pillars of Survival" (now the SOCA paradigm), the results were undeniable. AstraZeneca drove their Phase III success rate from a dismal 4% to 19% (1), while Pfizer saw a tenfold impr
evadanielson55
Apr 144 min read


Offspring Biosciences Special Feature: ✨Best in Stain ✨
Beyond their visual impact, these images represent something far more important: the power of spatial biology to reveal how biology truly functions within human tissue. #SpatialBiology #ScienceAsArt #Microscopy #SpatialBiology #Biotech
evadanielson55
Mar 312 min read


Decoding the Brain: The Evolving Challenge of Neurological Drug Development
Neurology is one of the most complex and challenging frontiers in medicine, encompassing a vast spectrum of disorders that affect the central and peripheral nervous system, behavioral and mood changes, and extending changes in hormones and the microbiome. This includes progressive neurodegenerative conditions like Alzheimer’s Disease and Parkinson’s Disease, defined by the toxic aggregation of proteins like Amyloid-beta and alpha-synuclein; autoimmune disorders like Multiple
evadanielson55
Mar 173 min read
bottom of page
